Skip to the main content

Review article

https://doi.org/10.20471/acc.2022.61.01.13

Common Variable Immunodeficiency: Predisposing or Protective Factor for Severe Complications of COVID-19?

Thomas Ferenc orcid id orcid.org/0000-0002-4917-9270 ; Department of Diagnostic and Interventional Radiology, Merkur University Hospital, Zagreb, Croatia
Tatjana Vilibić-Čavlek orcid id orcid.org/0000-0002-1877-5547 ; School of Medicine, University of Zagreb, Zagreb, Croatia; Department of Virology, Croatian Institute of Public Health, Zagreb, Croatia


Full text: english pdf 445 Kb

page 107-113

downloads: 445

cite


Abstract

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The usual presentation of the disease
is a common cold-like illness but it can present with more severe and sometimes fatal manifestations.
Immunocompromised patients such as those with common variable immunodeficiency (CVID)
also are among the infected population. A limited number of reports have been published concerning
CVID patients with COVID-19. The main reported symptoms were fever, cough, dyspnea and fatigue
while the median duration of illness was 19 (interquartile range 14-26.5) days. Total recovery rate was
88.4%. It is still unknown whether primary immunodeficiency interacts as a predisposing or protective
factor against the severe forms of COVID-19. Substitute immunoglobulin (IG) therapy is the only
treatment option for CVID. Some reports suggest that early administration of intravenous IGs or
convalescent plasma infusion may positively influence the outcome of COVID-19 in these patients.

Keywords

Common variable immunodeficiency; COVID-19; SARS-CoV-2

Hrčak ID:

280251

URI

https://hrcak.srce.hr/280251

Publication date:

1.3.2022.

Article data in other languages: croatian

Visits: 1.507 *